Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Insight into Novel Delivery Approaches of Resveratrol for Improving Therapeutic Efficacy and Bioavailability with its Clinical Updates

Author(s): Ranjit K. Harwansh*, Paras Yadav and Rohitas Deshmukh

Volume 29, Issue 37, 2023

Published on: 05 December, 2023

Page: [2921 - 2939] Pages: 19

DOI: 10.2174/0113816128282713231129094715

Price: $65

Abstract

Resveratrol (RSV) is a polyphenolic phytoalexin, and belongs to the stilbene family. RSV has several therapeutic activities such as cardioprotective, anticancer, and antioxidant. Apart from its therapeutic benefits, its pharmacological uses are limited due to low solubility, poor bioavailability, and short biological halflife. A researcher continuously focuses on overcoming the limitations of RSV through nanotechnology platforms to get the optimum health benefits. In this context, nanocarriers are pioneering to overcome these drawbacks. Nanocarriers possess high drug loading capacity, thermal stability, low production cost, longer shelflife, etc. Fortunately, scientists were proficient in delivering resveratrol-based nanocarriers in the present scenario. Nanocarriers can deliver drugs to the target sites without compromising the bioavailability. Thus, this review highlights how the latest nanocarrier systems overcome the shortcomings of RSV, which will be good for improving therapeutic efficacy and bioavailability. Moreover, recent updates on resveratrol-based novel formulations and their clinical trials have been addressed to manage several health-related problems.

Keywords: Resveratrol, polyphenolic, nanocarriers, herbal bioactive, bioavailability, half-life.

Next »
[1]
Subramanian P. Lipid-based nanocarrier system for the effective delivery of nutraceuticals. Molecules 2021; 26(18): 5510.
[http://dx.doi.org/10.3390/molecules26185510] [PMID: 34576981]
[2]
Wang W, Tang K, Yang HR, et al. Distribution of resveratrol and stilbene synthase in young grape plants (Vitis vinifera L. cv. Cabernet Sauvignon) and the effect of UV-C on its accumulation. Plant Physiol Biochem 2010; 48(2-3): 142-52.
[http://dx.doi.org/10.1016/j.plaphy.2009.12.002] [PMID: 20060310]
[3]
Feng J, Ren H, Gou Q, Zhu L, Ji H, Yi T. Comparative analysis of the major constituents in three related polygonaceous medicinal plants using pressurized liquid extraction and HPLC-ESI/MS. Anal Methods 2016; 8(7): 1557-64.
[http://dx.doi.org/10.1039/C5AY02941D]
[4]
Lin MH, Hung CF, Sung HC, Yang SC, Yu HP, Fang JY. The bioactivities of resveratrol and its naturally occurring derivatives on skin. Yao Wu Shi Pin Fen Xi 2021; 29(1): 15-38.
[http://dx.doi.org/10.38212/2224-6614.1151] [PMID: 35696226]
[5]
Singh G. Resveratrol: Nanocarrier-based delivery systems to enhance its therapeutic potential. Nanomedicine 2020; 15(28): 2801-17.
[http://dx.doi.org/10.2217/nnm-2020-0289] [PMID: 33191840]
[6]
Harwansh RK, Yadav M, Deshmukh R, Rahman A. Recent insights into nanoparticulate carrier systems of curcumin and its clinical perspective in the management of various health issues. Curr Pharm Des 2023; 29(18): 1421-40.
[http://dx.doi.org/10.2174/1381612829666230613115447] [PMID: 37312443]
[7]
Cheng CK, Luo JY, Lau CW, Chen ZY, Tian XY, Huang Y. Pharmacological basis and new insights of resveratrol action in the cardiovascular system. Br J Pharmacol 2020; 177(6): 1258-77.
[http://dx.doi.org/10.1111/bph.14801] [PMID: 31347157]
[8]
Fonseca-Santos B, Chorilli M. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. Int J Pharm 2020; 589: 119832.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119832] [PMID: 32877730]
[9]
Sergides C, Chirilă M, Silvestro L, Pitta D, Pittas A. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp Ther Med 2016; 11(1): 164-70.
[http://dx.doi.org/10.3892/etm.2015.2895] [PMID: 26889234]
[10]
Pentek T, Newenhouse E, O’Brien B, Chauhan A. Development of a topical resveratrol formulation for commercial applications using dendrimer nanotechnology. Molecules 2017; 22(1): 137.
[http://dx.doi.org/10.3390/molecules22010137] [PMID: 28098828]
[11]
Jhaveri A, Deshpande P, Pattni B, Torchilin V. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 2018; 277: 89-101.
[http://dx.doi.org/10.1016/j.jconrel.2018.03.006] [PMID: 29522834]
[12]
Yen CC, Chang CW, Hsu MC, Wu YT. Self-nanoemulsifying drug delivery system for resveratrol: Enhanced oral bioavailability and reduced physical fatigue in rats. Int J Mol Sci 2017; 18(9): 1853.
[http://dx.doi.org/10.3390/ijms18091853] [PMID: 28841149]
[13]
Zhang L, Zhu K, Zeng H, et al. Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity. Int J Nanomedicine 2019; 14: 6061-71.
[http://dx.doi.org/10.2147/IJN.S211130] [PMID: 31534336]
[14]
Kuk DH, Ha ES, Ha DH, et al. Development of a resveratrol nanosuspension using the antisolvent precipitation method without solvent removal, based on a quality by design (qbd) approach. Pharmaceutics 2019; 11(12): 688.
[http://dx.doi.org/10.3390/pharmaceutics11120688] [PMID: 31861173]
[15]
Isely C, Hendley MA, Murphy KP, et al. Development of microparticles for controlled release of resveratrol to adipose tissue and the impact of drug loading on particle morphology and drug release. Int J Pharm 2019; 568: 118469.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118469] [PMID: 31265884]
[16]
Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis Oncol 2017; 1(1): 35.
[http://dx.doi.org/10.1038/s41698-017-0038-6] [PMID: 28989978]
[17]
Parekh P, Motiwale L, Naik N, Rao KVK. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 2011; 63(1-2): 167-73.
[http://dx.doi.org/10.1016/j.etp.2009.11.005] [PMID: 20133117]
[18]
Kundu JK, Shin YK, Kim SH, Surh YJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity. Carcinogenesis 2006; 27(7): 1465-74.
[http://dx.doi.org/10.1093/carcin/bgi349] [PMID: 16474181]
[19]
Singh G, Pai RS. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release 2014; 194: 178-88.
[http://dx.doi.org/10.1016/j.jconrel.2014.09.002] [PMID: 25217813]
[20]
Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 2012; 18(1): 27-33.
[http://dx.doi.org/10.2174/138161212798919075] [PMID: 22211686]
[21]
Deshmukh R, Harwansh RK, Paul SD, Shukla R. Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease. J Drug Deliv Sci Technol 2020; 55: 101495.
[http://dx.doi.org/10.1016/j.jddst.2019.101495]
[22]
Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: The challenges ahead. Lancet 2009; 374(9696): 1196-208.
[http://dx.doi.org/10.1016/S0140-6736(09)61460-4] [PMID: 19801098]
[23]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
[http://dx.doi.org/10.2337/diacare.27.5.1047] [PMID: 15111519]
[24]
Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010; 316(2): 104-8.
[http://dx.doi.org/10.1016/j.mce.2009.07.008] [PMID: 19628019]
[25]
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49(11): 1603-16.
[http://dx.doi.org/10.1016/j.freeradbiomed.2010.09.006] [PMID: 20840865]
[26]
Pezzuto JM. Resveratrol as an inhibitor of carcinogenesis. Pharm Biol 2008; 46(7-8): 443-573.
[http://dx.doi.org/10.1080/13880200802116610]
[27]
Pervaiz S, Holme AL. Resveratrol: Its biologic targets and functional activity. Antioxid Redox Signal 2009; 11(11): 2851-97.
[http://dx.doi.org/10.1089/ars.2008.2412] [PMID: 19432534]
[28]
Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635(1-3): 1-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.02.054] [PMID: 20303945]
[29]
Harikumar KB, Aggarwal BB. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7(8): 1020-35.
[http://dx.doi.org/10.4161/cc.7.8.5740] [PMID: 18414053]
[30]
Bishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev Res 2009; 2(5): 409-18.
[http://dx.doi.org/10.1158/1940-6207.CAPR-08-0160] [PMID: 19401532]
[31]
Shakibaei M, Csaki C, Nebrich S, Mobasheri A. Resveratrol suppresses interleukin-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008; 76(11): 1426-39.
[http://dx.doi.org/10.1016/j.bcp.2008.05.029] [PMID: 18606398]
[32]
Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: A natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 2008; 14(3): 234-47.
[http://dx.doi.org/10.1111/j.1755-5949.2008.00045.x] [PMID: 18684235]
[33]
Markus MA, Morris BJ. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 2008; 3(2): 331-9.
[PMID: 18686754]
[34]
Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol Biomarkers Prev 2003; 12(10): 953-7.
[PMID: 14578128]
[35]
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
[http://dx.doi.org/10.1038/nrd2060] [PMID: 16732220]
[36]
de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochem Soc Trans 2007; 35(5): 1156-60.
[http://dx.doi.org/10.1042/BST0351156] [PMID: 17956300]
[37]
Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70(22): 9003-11.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2364] [PMID: 20935227]
[38]
Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular nutrapharmacology of resveratrol: Pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem 2010; 17(23): 2442-55.
[http://dx.doi.org/10.2174/092986710791556032] [PMID: 20491649]
[39]
Orallo F. Comparative studies of the antioxidant effects of cis-and trans-resveratrol. Curr Med Chem 2006; 13(1): 87-98.
[http://dx.doi.org/10.2174/092986706775197962] [PMID: 16457641]
[40]
Burkon A, Somoza V. Quantification of free and protein-boundtrans-resveratrol metabolites and identification oftrans-resveratrol-C/O-conjugated diglucuronides – Two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008; 52(5): 549-57.
[http://dx.doi.org/10.1002/mnfr.200700290] [PMID: 18435437]
[41]
Caruso F, Tanski J, Villegas-Estrada A, Rossi M. Structural basis for antioxidant activity of trans-resveratrol: ab initio calculations and crystal and molecular structure. J Agric Food Chem 2004; 52(24): 7279-85.
[http://dx.doi.org/10.1021/jf048794e] [PMID: 15563207]
[42]
Langcake P, Cornford CA, Pryce RJ. Identification of pterostilbene as a phytoalexin from Vitis vinifera leaves. Phytochemistry 1979; 18(6): 1025-7.
[http://dx.doi.org/10.1016/S0031-9422(00)91470-5]
[43]
Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 1976; 9(1): 77-86.
[http://dx.doi.org/10.1016/0048-4059(76)90077-1]
[44]
Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215(1): 9-15.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05842.x] [PMID: 21261636]
[45]
Kuhnle G, Spencer JPE, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000; 272(1): 212-7.
[http://dx.doi.org/10.1006/bbrc.2000.2750] [PMID: 10872829]
[46]
Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008; 46(11): 564-70.
[http://dx.doi.org/10.5414/CPP46564] [PMID: 19000554]
[47]
la Porte C, Voduc N, Zhang G, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49(7): 449-54.
[http://dx.doi.org/10.2165/11531820-000000000-00000] [PMID: 20528005]
[48]
Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability oftrans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49(5): 495-504.
[http://dx.doi.org/10.1002/mnfr.200500002] [PMID: 15830336]
[49]
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32(12): 1377-82.
[http://dx.doi.org/10.1124/dmd.104.000885] [PMID: 15333514]
[50]
Wenzel E, Somoza V. Metabolism and bioavailability oftrans-resveratrol. Mol Nutr Food Res 2005; 49(5): 472-81.
[http://dx.doi.org/10.1002/mnfr.200500010] [PMID: 15779070]
[51]
Brisdelli F, D’Andrea G, Bozzi A. Resveratrol: A natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 2009; 10(6): 530-46.
[http://dx.doi.org/10.2174/138920009789375423] [PMID: 19702538]
[52]
Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans -resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53(S1) (Suppl. 1): S7-S15.
[http://dx.doi.org/10.1002/mnfr.200800177] [PMID: 19194969]
[53]
Jannin B, Menzel M, Berlot JP, Delmas D, Lançon A, Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: Plasmatic protein binding and cell uptake. Biochem Pharmacol 2004; 68(6): 1113-8.
[http://dx.doi.org/10.1016/j.bcp.2004.04.028] [PMID: 15313407]
[54]
Lu Z, Zhang Y, Liu H, Yuan J, Zheng Z, Zou G. Transport of a cancer chemopreventive polyphenol, resveratrol: Interaction with serum albumin and hemoglobin. J Fluoresc 2007; 17(5): 580-7.
[http://dx.doi.org/10.1007/s10895-007-0220-2] [PMID: 17597382]
[55]
Patel KR, Brown VA, Jones DJL, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70(19): 7392-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2027] [PMID: 20841478]
[56]
Boocock DJ, Faust GES, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16(6): 1246-52.
[http://dx.doi.org/10.1158/1055-9965.EPI-07-0022] [PMID: 17548692]
[57]
Luca SV, Macovei I, Bujor A, et al. Bioactivity of dietary polyphenols: The role of metabolites. Crit Rev Food Sci Nutr 2020; 60(4): 626-59.
[http://dx.doi.org/10.1080/10408398.2018.1546669] [PMID: 30614249]
[58]
Singh AP, Singh R, Verma SS, et al. Health benefits of resveratrol: Evidence from clinical studies. Med Res Rev 2019; 39(5): 1851-91.
[http://dx.doi.org/10.1002/med.21565] [PMID: 30741437]
[59]
Xia N, Daiber A, Förstermann U, Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol 2017; 174(12): 1633-46.
[http://dx.doi.org/10.1111/bph.13492] [PMID: 27058985]
[60]
Tai TY, Chuang LM, Chen CJ, Lin BJ. Link between hypertension and diabetes mellitus epidemiological study of Chinese adults in Taiwan. Diabetes Care 1991; 14(11): 1013-20.
[http://dx.doi.org/10.2337/diacare.14.11.1013] [PMID: 1797481]
[61]
Ziyyat A, Ramdani N, Bouanani NEH, et al. Epidemiology of hypertension and its relationship with type 2 diabetes and obesity in Eastern Morocco. Springerplus 2014; 3(1): 644.
[http://dx.doi.org/10.1186/2193-1801-3-644] [PMID: 25392811]
[62]
Konings E, Timmers S, Boekschoten MV, et al. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int J Obes 2014; 38(3): 470-3.
[http://dx.doi.org/10.1038/ijo.2013.155] [PMID: 23958793]
[63]
Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 2012; 64(3): 393-400.
[http://dx.doi.org/10.1080/01635581.2012.654926] [PMID: 22332908]
[64]
Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94(8): 606-16.
[http://dx.doi.org/10.1093/jnci/94.8.606] [PMID: 11959894]
[65]
Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91(12): 1067-72.
[http://dx.doi.org/10.1093/jnci/91.12.1067] [PMID: 10379970]
[66]
Ruan X, Seeger H, Wallwiener D, Huober J, Mueck AO. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: Two case–control studies. Arch Gynecol Obstet 2015; 291(5): 1141-6.
[http://dx.doi.org/10.1007/s00404-014-3512-1] [PMID: 25318606]
[67]
Chow HHS, Garland LL, Heckman-Stoddard BM, et al. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. J Transl Med 2014; 12(1): 223.
[http://dx.doi.org/10.1186/s12967-014-0223-0] [PMID: 25115686]
[68]
Göçmen AY, Burgucu D, Gümüşlü S. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40–CD40L system as a potential target. Appl Physiol Nutr Metab 2011; 36(3): 323-30.
[http://dx.doi.org/10.1139/h11-022] [PMID: 21574786]
[69]
Haskó G, Pacher P. Endothelial Nrf2 activation: A new target for resveratrol? Am J Physiol Heart Circ Physiol 2010; 299(1): H10-2.
[http://dx.doi.org/10.1152/ajpheart.00436.2010] [PMID: 20472762]
[70]
Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and A po B in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 2012; 56(5): 810-21.
[http://dx.doi.org/10.1002/mnfr.201100673] [PMID: 22648627]
[71]
Taeye BD, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5(2): 149-54.
[http://dx.doi.org/10.1016/j.coph.2005.01.007] [PMID: 15780823]
[72]
Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventós RM, et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol Res 2012; 65(6): 615-20.
[http://dx.doi.org/10.1016/j.phrs.2012.03.009] [PMID: 22465220]
[73]
Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013; 29(1): 178-83.
[http://dx.doi.org/10.1016/j.nut.2012.07.006] [PMID: 23153742]
[74]
Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50(3): 179-87.
[http://dx.doi.org/10.3233/CH-2011-1424] [PMID: 22240353]
[75]
Boo YC. Human skin lightening efficacy of resveratrol and its analogs: From in vitro studies to cosmetic applications. Antioxidants 2019; 8(9): 332.
[http://dx.doi.org/10.3390/antiox8090332] [PMID: 31443469]
[76]
Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001; 62(9): 1299-308.
[http://dx.doi.org/10.1016/S0006-2952(01)00775-4] [PMID: 11705464]
[77]
Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275(5297): 218-20.
[http://dx.doi.org/10.1126/science.275.5297.218] [PMID: 8985016]
[78]
Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory response in the rat hippocampus following global cerebral ischemia. Neurochem Int 2012; 61(5): 659-65.
[http://dx.doi.org/10.1016/j.neuint.2012.06.009] [PMID: 22709670]
[79]
Hou Y, Zhang Y, Mi Y, et al. A novel quinolyl-substituted analogue of resveratrol inhibits lps-induced inflammatory responses in microglial cells by blocking the NF-κB/MAPK signaling pathways. Mol Nutr Food Res 2019; 63(20): 1801380.
[http://dx.doi.org/10.1002/mnfr.201801380]
[80]
Jiang H, Duan J, Xu K, Zhang W. Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway. Exp Ther Med 2019; 18(1): 459-66.
[http://dx.doi.org/10.3892/etm.2019.7594] [PMID: 31258683]
[81]
Shi G, Hua M, Xu Q, Ren T. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial. Immunobiology 2017; 222(2): 164-8.
[http://dx.doi.org/10.1016/j.imbio.2016.10.008] [PMID: 27771172]
[82]
Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95(9): E1-8.
[http://dx.doi.org/10.1210/jc.2010-0482] [PMID: 20534755]
[83]
Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 2013; 72: 69-82.
[http://dx.doi.org/10.1016/j.phrs.2013.03.011] [PMID: 23557933]
[84]
Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013; 27(1): 37-48.
[http://dx.doi.org/10.1007/s10557-012-6427-8] [PMID: 23224687]
[85]
Williams CB, Hughes MC, Edgett BA, et al. An examination of resveratrol’s mechanisms of action in human tissue: Impact of a single dose in vivo and dose responses in skeletal muscle ex vivo. PLoS One 2014; 9(7): e102406.
[http://dx.doi.org/10.1371/journal.pone.0102406] [PMID: 25019209]
[86]
Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism. J Biol Chem 2010; 285(12): 9100-13.
[http://dx.doi.org/10.1074/jbc.M109.060061] [PMID: 20080969]
[87]
Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59(3): 554-63.
[http://dx.doi.org/10.2337/db09-0482] [PMID: 19934007]
[88]
Kou X, Chen N. Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer’s disease. Nutrients 2017; 9(9): 927.
[http://dx.doi.org/10.3390/nu9090927] [PMID: 28837083]
[89]
Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5(4): 496-504.
[http://dx.doi.org/10.1021/mp800049w] [PMID: 18611037]
[90]
Heredia A, Davis C, Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr 2000; 25(3): 246-55.
[http://dx.doi.org/10.1097/00126334-200011010-00006] [PMID: 11115955]
[91]
Touzet O, Philips A. Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS 2010; 24(10): 1437-47.
[http://dx.doi.org/10.1097/QAD.0b013e32833a6114] [PMID: 20539089]
[92]
Langer R. Drug delivery and targeting. Nature 1998; 392(6679) (Suppl.): 5-10.
[PMID: 9579855]
[93]
Bahadur S, Sachan N, Harwansh RK, Deshmukh R. Nanoparticlized system: Promising approach for the management of Alzheimer’s disease through intranasal delivery. Curr Pharm Des 2020; 26(12): 1331-44.
[http://dx.doi.org/10.2174/1381612826666200311131658] [PMID: 32160843]
[94]
Krambeck K, Silva V, Silva R, et al. Design and characterization of Nanostructured lipid carriers (NLC) and Nanostructured lipid carrier-based hydrogels containing Passiflora edulis seeds oil. Int J Pharm 2021; 600: 120444.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120444] [PMID: 33713760]
[95]
Ali HE, Radwan RR. Synthesis, characterization and evaluation of resveratrol-loaded functionalized carbon nanotubes as a novel delivery system in radiation enteropathy. Eur J Pharm Sci 2021; 167: 106002.
[http://dx.doi.org/10.1016/j.ejps.2021.106002] [PMID: 34517108]
[96]
Theodorakis PE, Che Z. Surface nanobubbles: Theory, simulation, and experiment. A review. Adv Colloid Interface Sci 2019; 272: 101995.
[http://dx.doi.org/10.1016/j.cis.2019.101995] [PMID: 31394435]
[97]
Shen J, Zhuo N, Xu S, et al. Resveratrol delivery by ultrasound-mediated nanobubbles targeting nucleus pulposus cells. Nanomedicine 2018; 13(12): 1433-46.
[http://dx.doi.org/10.2217/nnm-2018-0019] [PMID: 29658365]
[98]
Zupančič Š. Core-shell nanofibers as drug delivery systems. Acta Pharm 2019; 69(2): 131-53.
[http://dx.doi.org/10.2478/acph-2019-0014] [PMID: 31259723]
[99]
Rostami M, Ghorbani M, Aman mohammadi M, Delavar M, Tabibiazar M, Ramezani S. Development of resveratrol loaded chitosan-gellan nanofiber as a novel gastrointestinal delivery system. Int J Biol Macromol 2019; 135: 698-705.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.05.187] [PMID: 31145955]
[100]
Verma S, Utreja P. Vesicular nanocarrier based treatment of skin fungal infections: Potential and emerging trends in nanoscale pharmacotherapy. Asian J Pharm Clin 2019; 14(2): 117-29.
[http://dx.doi.org/10.1016/j.ajps.2018.05.007] [PMID: 32104444]
[101]
Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012; 163(1): 34-45.
[http://dx.doi.org/10.1016/j.jconrel.2012.06.002] [PMID: 22698939]
[102]
Bahadur S, Sharma M. Liposome based drug delivery for the management of psoriasis-A comprehensive review. Curr Pharm Biotechnol 2022.
[PMID: 36518042]
[103]
Khorasani S, Danaei M, Mozafari MR. Nanoliposome technology for the food and nutraceutical industries. Trends Food Sci Technol 2018; 79: 106-15.
[http://dx.doi.org/10.1016/j.tifs.2018.07.009]
[104]
Mozafari MR. Nanoliposomes: Preparation and analysis. Methods Mol Biol. 2010; 605: pp. 29-50.
[http://dx.doi.org/10.1007/978-1-60327-360-2_2]
[105]
Caddeo C, Gabriele M, Nácher A, et al. Resveratrol and artemisinin eudragit-coated liposomes: A strategy to tackle intestinal tumors. Int J Pharm 2021; 592: 120083.
[http://dx.doi.org/10.1016/j.ijpharm.2020.120083] [PMID: 33197563]
[106]
Jagwani S, Jalalpure S, Dhamecha D, Jadhav K, Bohara R. Pharmacokinetic and pharmacodynamic evaluation of resveratrol loaded cationic liposomes for targeting hepatocellular carcinoma. ACS Biomater Sci Eng 2020; 6(9): 4969-84.
[http://dx.doi.org/10.1021/acsbiomaterials.0c00429] [PMID: 33455290]
[107]
Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 2002; 251(2): 360-5.
[http://dx.doi.org/10.1006/jcis.2002.8399] [PMID: 16290741]
[108]
Mohamed HB, El-Shanawany SM, Hamad MA, Elsabahy M. Niosomes: A strategy toward prevention of clinically significant drug incompatibilities. Sci Rep 2017; 7(1): 6340.
[http://dx.doi.org/10.1038/s41598-017-06955-w] [PMID: 28740102]
[109]
Pando D, Beltrán M, Gerone I, Matos M, Pazos C. Resveratrol entrapped niosomes as yoghurt additive. Food Chem 2015; 170: 281-7.
[http://dx.doi.org/10.1016/j.foodchem.2014.08.082] [PMID: 25306346]
[110]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017; 264: 306-32.
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033] [PMID: 28844756]
[111]
Agrawal S, Garg A, Varshney V. Recent updates on applications of lipid-based nanoparticles for site-specific drug delivery. Pharm Nanotechnol 2022; 10(1): 24-41.
[http://dx.doi.org/10.2174/2211738510666220304111848] [PMID: 35249522]
[112]
Gaur PK, Mishra S, Bajpai M, Mishra A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: In vitro drug release and pharmacokinetics studies. Biomed Res Int 2014; 2014: 363404.
[113]
Serini S, Cassano R, Corsetto P, Rizzo A, Calviello G, Trombino S. Omega-3 PUFA loaded in resveratrol-based solid lipid nanoparticles: physicochemical properties and antineoplastic activities in human colorectal cancer cells in vitro. Int J Mol Sci 2018; 19(2): 586.
[http://dx.doi.org/10.3390/ijms19020586] [PMID: 29462928]
[114]
Cassano R, Serini S, Curcio F, Trombino S, Calviello G. Preparation and study of solid lipid nanoparticles based on curcumin, resveratrol and capsaicin containing linolenic acid. Pharmaceutics 2022; 14(8): 1593.
[http://dx.doi.org/10.3390/pharmaceutics14081593] [PMID: 36015219]
[115]
Soldati PP, Polonini HC, Paes CQ, et al. Controlled release of resveratrol from lipid nanoparticles improves antioxidant effect. IFAC-PapersOnLine 2018; 51(27): 16-21.
[http://dx.doi.org/10.1016/j.ifacol.2018.11.600]
[116]
Serini S, Cassano R, Facchinetti E, Amendola G, Trombino S, Calviello G. Anti-irritant and anti-inflammatory effects of DHA encapsulated in resveratrol-based solid lipid nanoparticles in human keratinocytes. Nutrients 2019; 11(6): 1400.
[http://dx.doi.org/10.3390/nu11061400] [PMID: 31234344]
[117]
Song Z, Shi Y, Han Q, Dai G. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Biomed Pharmacother 2018; 105: 18-26.
[http://dx.doi.org/10.1016/j.biopha.2018.05.095] [PMID: 29843041]
[118]
Mohseni R, ArabSadeghabadi Z, Ziamajidi N, Abbasalipourkabir R, RezaeiFarimani A. Oral administration of resveratrol-loaded solid lipid nanoparticle improves insulin resistance through targeting expression of SNARE proteins in adipose and muscle tissue in rats with type 2 diabetes. Nanoscale Res Lett 2019; 14(1): 227.
[http://dx.doi.org/10.1186/s11671-019-3042-7] [PMID: 31290033]
[119]
Shimojo AAM, Fernandes ARV, Ferreira NRE, Sanchez-Lopez E, Santana MHA, Souto EB. Evaluation of the influence of process parameters on the properties of resveratrol-loaded NLC Using 22 full factorial design. Antioxidants 2019; 8(8): 272.
[http://dx.doi.org/10.3390/antiox8080272] [PMID: 31382599]
[120]
Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol 2019; 51: 214-23.
[http://dx.doi.org/10.1016/j.jddst.2019.01.040]
[121]
Miao L, Daozhou L, Ying C, Qibing M, Siyuan Z. A resveratrol-loaded nanostructured lipid carrier hydrogel to enhance the anti-UV irradiation and anti-oxidant efficacy. Colloids Surf B Biointerfaces 2021; 204: 111786.
[http://dx.doi.org/10.1016/j.colsurfb.2021.111786] [PMID: 33984613]
[122]
Houacine C, Adams D, Singh KK. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. J Mol Liq 2020; 316: 113734.
[http://dx.doi.org/10.1016/j.molliq.2020.113734]
[123]
Hosseini Berenji R, Pezeshki A, Ghanbarzadeh B, et al. Resveratrol entrapped food grade lipid nanocarriers as a potential antioxidant in a mayonnaise. Food Biosci 2021; 41: 101041.
[http://dx.doi.org/10.1016/j.fbio.2021.101041]
[124]
Astley C, Houacine C, Zaabalawi A, et al. Nanostructured lipid carriers deliver resveratrol, restoring attenuated dilation in small coronary arteries, via the AMPK pathway. Biomedicines 2021; 9(12): 1852.
[http://dx.doi.org/10.3390/biomedicines9121852] [PMID: 34944670]
[125]
Merkle HP. Drug delivery’s quest for polymers: Where are the frontiers? Eur J Pharm Biopharm 2015; 97(Pt B): 293-303.
[http://dx.doi.org/10.1016/j.ejpb.2015.04.038] [PMID: 26614554]
[126]
Sajid M, Płotka-Wasylka J. Nanoparticles: Synthesis, characteristics, and applications in analytical and other sciences. Microchem J 2020; 154: 104623.
[http://dx.doi.org/10.1016/j.microc.2020.104623]
[127]
Bangde P, Atale S, Dey A, Pandit A, Dandekar P, Jain R. Potential gene therapy towards treating neurodegenerative disea ses employing polymeric nanosystems. Curr Gene Ther 2017; 17(2): 170-83.
[PMID: 28494742]
[128]
Zhao K, Li D, Shi C, et al. Biodegradable polymeric nanoparticles as the delivery carrier for drug. Curr Drug Deliv 2016; 13(4): 494-9.
[http://dx.doi.org/10.2174/156720181304160521004609] [PMID: 27230997]
[129]
Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci 2018; 5(11): 181457.
[http://dx.doi.org/10.1098/rsos.181457] [PMID: 30564426]
[130]
Yang C, Wang Y, Xie Y, et al. Oat protein-shellac nanoparticles as a delivery vehicle for resveratrol to improve bioavailability in vitro and in vivo. Nanomedicine 2019; 14(21): 2853-71.
[http://dx.doi.org/10.2217/nnm-2019-0244] [PMID: 31752574]
[131]
Santos AC, Veiga FJ, Sequeira JAD, et al. First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats-a pharmacokinetics study. Analyst 2019; 144(6): 2062-79.
[http://dx.doi.org/10.1039/C8AN01998C] [PMID: 30724915]
[132]
Penalva R, Esparza I, Larraneta E, González-Navarro CJ, Gamazo C, Irache JM. Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. J Agric Food Chem 2015; 63(23): 5603-11.
[http://dx.doi.org/10.1021/jf505694e] [PMID: 26027429]
[133]
Liping Y, Jian H, Zhenchao T, et al. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance. Drug Deliv 2022; 29(1): 229-37.
[http://dx.doi.org/10.1080/10717544.2021.2023700] [PMID: 35001781]
[134]
Dai L, Li Y, Kong F, Liu K, Si C, Ni Y. Lignin-based nanoparticles stabilized pickering emulsion for stability improvement and thermal-controlled release of trans-resveratrol. ACS Sustain Chem Eng 2019; 7(15): 13497-504.
[http://dx.doi.org/10.1021/acssuschemeng.9b02966]
[135]
Zhang L, Zhang F, Fang Y, Wang S. Alginate-shelled SPI nanoparticle for encapsulation of resveratrol with enhanced colloidal and chemical stability. Food Hydrocoll 2019; 90: 313-20.
[http://dx.doi.org/10.1016/j.foodhyd.2018.12.042]
[136]
Cinan E, Cesur S, Erginer Haskoylu M, Gunduz O, Toksoy Oner E. Resveratrol-loaded levan nanoparticles produced by electrohydrodynamic atomization technique. Nanomaterials 2021; 11(10): 2582.
[http://dx.doi.org/10.3390/nano11102582] [PMID: 34685023]
[137]
Samprasit W, Opanasopit P, Chamsai B. Alpha-mangostin and resveratrol, dual-drugs-loaded mucoadhesive thiolated chitosan-based nanoparticles for synergistic activity against colon cancer cells. J Biomed Mater Res B Appl Biomater 2022; 110(6): 1221-33.
[http://dx.doi.org/10.1002/jbm.b.34992] [PMID: 34919783]
[138]
Gumireddy A, Christman R, Kumari D, Tiwari A, North EJ, Chauhan H. Preparation, characterization, and in vitro evaluation of curcumin-and resveratrol-loaded solid lipid nanoparticles. AAPS PharmSciTech 2019; 20(4): 145.
[http://dx.doi.org/10.1208/s12249-019-1349-4] [PMID: 30887133]
[139]
Wang Y, Ma J, Qiu T, Tang M, Zhang X, Dong W. In vitro and in vivo combinatorial anticancer effects of oxaliplatin-and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer. Eur J Pharm Sci 2021; 163: 105864.
[http://dx.doi.org/10.1016/j.ejps.2021.105864] [PMID: 33965502]
[140]
Amanat S, Taymouri S, Varshosaz J, Minaiyan M, Talebi A. Carboxymethyl cellulose-based wafer enriched with resveratrol-loaded nanoparticles for enhanced wound healing. Drug Deliv Transl Res 2020; 10(5): 1241-54.
[http://dx.doi.org/10.1007/s13346-020-00711-w] [PMID: 31981141]
[141]
Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)–Poly(ethylene glycol) blend for prostate cancer treatment. Mol Pharm 2013; 10(10): 3871-81.
[http://dx.doi.org/10.1021/mp400342f] [PMID: 23968375]
[142]
Meena J, Gupta A, Ahuja R, Singh M, Bhaskar S, Panda AK. Inorganic nanoparticles for natural product delivery: A review. Environ Chem Lett 2020; 18(6): 2107-18.
[http://dx.doi.org/10.1007/s10311-020-01061-2]
[143]
Preethi R, Padma P. Biosynthesis and bioactivity of silver nanobioconjugates from grape (Vitis vinifera) seeds and its active component resveratrol. Int J Pharm Sci Res 2016; 7: 4253.
[144]
Summerlin N, Qu Z, Pujara N, et al. Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids Surf B Biointerfaces 2016; 144: 1-7.
[http://dx.doi.org/10.1016/j.colsurfb.2016.03.076] [PMID: 27060664]
[145]
Pinilla-Peñalver E, García-Béjar B, Contento AM, Ríos Á. Graphene quantum dots an efficient nanomaterial for enhancing the photostability of trans-resveratrol in food samples. Food Chem 2022; 386: 132766.
[http://dx.doi.org/10.1016/j.foodchem.2022.132766] [PMID: 35349896]
[146]
Zhang D, Zhang J, Zeng J, et al. Nano-gold loaded with resveratrol enhance the anti-hepatoma effect of resveratrol in vitro and in vivo. J Biomed Nanotechnol 2019; 15(2): 288-300.
[http://dx.doi.org/10.1166/jbn.2019.2682] [PMID: 30596551]
[147]
Li X, Chen XX, Xu Y, et al. Construction of glycogen-based nanoparticles loaded with resveratrol for the alleviation of high-fat diet-induced nonalcoholic fatty liver disease. Biomacromolecules 2022; 23(1): 409-23.
[http://dx.doi.org/10.1021/acs.biomac.1c01360] [PMID: 34964604]
[148]
Fonseca DP, Khalil NM, Mainardes RM. Bovine serum albumin-based nanoparticles containing resveratrol: Characterization and antioxidant activity. J Drug Deliv Sci Technol 2017; 39: 147-55.
[http://dx.doi.org/10.1016/j.jddst.2017.03.017]
[149]
Liu Y, Gao L, Yi J, Fan Y, Wu X, Zhang Y. α-Lactalbumin and chitosan core–shell nanoparticles: Resveratrol loading, protection, and antioxidant activity. Food Funct 2020; 11(2): 1525-36.
[http://dx.doi.org/10.1039/C9FO01998G] [PMID: 31995080]
[150]
Fan Y, Zeng X, Yi J, Zhang Y. Fabrication of pea protein nanoparticles with calcium-induced cross-linking for the stabilization and delivery of antioxidative resveratrol. Int J Biol Macromol 2020; 152: 189-98.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.02.248] [PMID: 32105693]
[151]
Bi Yanping. Preparation method for magnetic nanoparticle-containing resveratrol composite nanosuspension. CN Patent 104224708A, 2014.
[152]
Zhang Hao, Wang Wenjing, Rong Li, Tang Qi, Yang Bai. Method for preparing gold@resveratrol multi-function nanometer composite photo-thermal reagent without using surfactant and composite photo-thermal reagent. CN Patent 106512005A, 2017.
[153]
Zhao Xiaoyan, Huang Chengzhi, Zhang Duoduo, Zhang Jie. The preparation method of gold nano load resveratrol. CN Patent 108159427A, 2018.
[154]
Tripathi V. Colloidally stable resveratrol nanoparticles with improved bioavailability and half-life and synthesis thereof. World Patent 137957A1, 2017.
[155]
Duan M, Zhou H, Yan Z. Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof. US Patent 8465757, 2013.
[156]
Dang HNT, Lai NH. Process for producing a nano resveratrol microemulsion system. US Patent 10882012, 2021.
[157]
Qiang XZW. Resveratrol nanostructured lipid carrier and preparation method thereof. CN Patent 102614091B, 2011.
[158]
Zhang Wanping, Liang Xiaozhi, Qin Yubo, Zhu Haiyang. Resveratrol-coated nano solid lipid carrier and preparation method thereof. CN Patent 105534724A, 2016.
[159]
Sharifi-Rad J, Quispe C, Mukazhanova Z, et al. Resveratrol-based nanoformulations as an emerging therapeutic strategy for cancer. Front Mol Biosci 2021; 8: 649395.
[http://dx.doi.org/10.3389/fmolb.2021.649395] [PMID: 34540888]
[160]
Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK, Babu RJ. Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep 2021; 4(3): e1353.
[http://dx.doi.org/10.1002/cnr2.1353] [PMID: 33655717]

Rights & Permissions Print Cite
Article Metrics
36
2
© 2024 Bentham Science Publishers | Privacy Policy